Prosecution Insights
Last updated: April 19, 2026
Application No. 18/551,834

UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS

Non-Final OA §102§103§112
Filed
Sep 21, 2023
Examiner
LEWIS, PATRICK T
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Customarray Inc.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
2y 6m
To Grant
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allow Rate
844 granted / 1135 resolved
+14.4% vs TC avg
Moderate +14% lift
Without
With
+14.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
40 currently pending
Career history
1175
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
30.5%
-9.5% vs TC avg
§102
20.4%
-19.6% vs TC avg
§112
21.4%
-18.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1135 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5-8 and 14-16 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 5 and 14, variable A in Formula (I) is not clearly defined in the claim(s). It is unclear whether applicant intends for the variable to be limited to a linking moiety attached to a coated platinum electrode…heterocyclic group, H, a substituted or unsubstituted aliphatic group, a substituted or unsubstituted aliphatic ether, a substituted or unsubstituted heteroalkyl group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heterocyclic group. Thus, one would not have been apprised of the metes and bounds of Formula (I). The deficiency is not rectified in claims 6-8 and 15-16. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claim(s) 1-2 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by McGall et al. US 2017/0067095 A1 (McGall). McGall teaches a solid support system comprising a planar surface and a universal linker as depicted in FIG. 7D. PNG media_image1.png 506 708 media_image1.png Greyscale The solid support system of McGall is embraced by the instant claims. Regarding the clause “wherein the planar surface is coated…universal linker” in claim 2, even though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. McGall teaches all of the instantly claimed elements. Thus, claims 1-2 are anticipated. Claim(s) 29 and 32-33 is/are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by McGall et al. US 2017/0067095 A1 (McGall). McGall teaches a cleavable linker having the structure: PNG media_image2.png 252 504 media_image2.png Greyscale . The linker of McGall is embraced a compound of Formula (XI), wherein X = acyl; Y = dimethoxytrityl group; and n = 3. Regarding the clause(s) “wherein the silyl is…or triisopropylsilyl” in claim 32 and “wherein the silyl is tert-butyldimethylsilyl” in claim 33, X is not limited to silyl. McGall teaches all of the instantly claimed elements. Thus, claims 29 and 32-33 are anticipated. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 30 is/are rejected under 35 U.S.C. 103 as being unpatentable over McGall et al. US 2017/0067095 A1 (McGall) as applied to claims 29 and 32-33 above. McGall differs from the instantly claimed invention in that McGall does not teach a compound wherein n is 5; however, that deficiency would have been prima facie obvious. A prima facie case of obviousness may be made when chemical compounds have very close structural similarities and similar utilities. “An obviousness rejection based on similarity in chemical structure and function entails the motivation of one skilled in the art to make a claimed compound, in the expectation that compounds similar in structure will have similar properties.” Compounds which are homologs (compounds differing regularly by the successive addition of the same chemical group, e.g., by -CH2- groups) are generally of sufficiently close structural similarity that there is a presumed expectation that such compounds possess similar properties. In re Wilder, 563 F.2d 457, 195 USPQ 426 (CCPA 1977). Conclusion Claims 1-2, 5-8, 10, 14-18, 20-21, 29-33, and 43 are pending. Claims 1-2, 5-8, 14-16, 29-30, and 32-33 are rejected. Claims 31 and 43 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claims 10, 17-18, and 20-21 are allowed. The following is a statement of reasons for the indication of allowable subject matter: McGall et al. US 2017/0067095 A1 (McGall) is representative of prior art. McGall differs from the instantly claimed invention in that McGall does not teach or suggest the instantly claimed methodological steps (e.g., coupling the surface with a universal linker). Contacts Any inquiry concerning this communication or earlier communications from the examiner should be directed to PATRICK T LEWIS whose telephone number is (571)272-0655. The examiner can normally be reached Monday to Friday, 10 AM to 4 PM EST (Maxi Flex). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached at (571) 272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PATRICK T LEWIS/Primary Examiner, Art Unit 1691 /PL/
Read full office action

Prosecution Timeline

Sep 21, 2023
Application Filed
Feb 18, 2026
Non-Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599594
Treatment Of Fabry Disease In ERT-Naïve And ERT-Experienced Patients
2y 5m to grant Granted Apr 14, 2026
Patent 12599595
Dosing Regimens for the Treatment of Lysosomal Storage Diseases Using Pharmacological Chaperones
2y 5m to grant Granted Apr 14, 2026
Patent 12595281
Indodicarbocyanine Phosphoramidites with Bathochromically Shifted Absorption and Emission, and Tunable Hydrophobicity
2y 5m to grant Granted Apr 07, 2026
Patent 12594292
ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS
2y 5m to grant Granted Apr 07, 2026
Patent 12584124
MAGNETIC BEAD BASED NUCLEIC ACID EXTRACTION SYSTEM
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.3%)
2y 6m
Median Time to Grant
Low
PTA Risk
Based on 1135 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month